FUS and amyotrophic lateral sclerosis: Altogether we identified 227 patients (∼10% of our cohort) that would be eligible for one of the three gene-specific therapies (SOD1/FUS/C9orf72), who would have remained undetected if the patient selection for genetic screening was solely based on the presence of a positive family history for ALS.